showed selective inhibition against ACAT2. In particular, pyripyropene A was found to be the most selective ACAT2 inhibitor with a selective index of more than 1,000.
Introduction
Acyl-CoA : cholesterol acyltransferase (ACAT), an ER membrane protein, is responsible for many functions in the body. ACAT has been recognized as a target for inhibition by a new type of antiatherosclerotic agents [1] . Many pharmaceutical laboratories have developed synthetic ACAT inhibitors. However, almost none of them could be successfully developed because of side effects or low in vivo efficacy [2] . Recent molecular biological studies revealed the existence in mammals of two different ACAT isozymes, ACAT1 and ACAT2 [3ϳ6] . ACAT1 is ubiquitously expressed in tissues and cells, while ACAT2 is expressed predominantly in the liver (hepatocytes) and intestine [7] . Therefore, it is important to determine the selectivity of inhibitors toward the two ACAT isozymes for their development as new antiatherosclerotic agents [8] . However, such data have rarely been reported so far [9, 10] .
Our research group discovered a number of microbial ACAT inhibitors with an enzyme assay using rat liver microsomes; these inhibitors included pyripyropenes [11ϳ13], purpactins [14, 15] , glisoprenins [16ϳ18] and terpendoles [19ϳ21] (Fig. 1) . The activities of these inhibitors in cell-based assays and their selectivity toward the two ACAT isozymes have not been fully studied. We also developed a cell-based assay of lipid droplet accumulation in mouse macrophages, and discovered beauveriolides [22ϳ25], phenochalasins [26, 27] , spylidone [28] , sespendole [29] and K97-0239s [30] with this assay (Fig. 2) . We studied the molecular targets of beauveriolides I and III in macrophages and found that they inhibited cholesteryl ester (CE) synthesis by blocking ACAT activity in macrophages, leading to the inhibition of lipid droplet accumulation. More importantly, they proved orally active in atherogenic mouse models and are expected to provide a new method for the prevention and treatment of atherosclerosis [31, 32] . However, the molecular targets of the other inhibitors are not yet well defined, and their effect on ACAT activity as a potential target should be studied.
Thus, we studied microbial inhibitors discovered by screening against ACAT ( Fig. 1) and lipid droplet accumulation (Fig. 2 ) by examining their inhibitory activity against ACAT1 and ACAT2 isozymes, and their selectivity toward the isozymes. For the examination, two cell lines, CHO cells expressing African Green monkey ACAT1 (ACAT1-CHO) and ACAT2 (ACAT2-CHO) were used [9] . [28] , sespendole [29] and K97-0239A and B [30] were purified from the culture broth of the respective producing microorganism according to the established methods. CL-283,546, a synthetic ACAT inhibitor, was a generous gift from J. Hess (Pfizer, USA). [1- was purchased from PerkinElmer Life and Analytical Sciences (USA). [1- 14 C]Oleoyl-coenzyme A was purchased from GE Healthcare Bio-Sciences (USA). Dulbecco's modified Eagle's medium (DMEM) and Hank's buffered salt solution (HBSS) were purchased from Nissui Pharmaceutical (Japan). GIT medium was from Nihon Pharmaceutical. Fetal bovine serum (FBS) was from HyClone (USA). HAM's F12, phosphatidylcholine, phosphatidylserine, diacetylphosphate, cholesterol, and fatty acid-free bovine serum albumin (BSA) were obtained from Sigma-Aldrich (USA). Geneticin (G-418 sulfate) and MEM vitamin solution were from Wako Pure Chemical Industries (Japan). Penicillin (10,000 units/ml)/ streptomycin (10,000 mg/ml) and L-glutamine (200 mM) solution were from Invitrogen (USA). Plastic microplates (48-well) were purchased from Asahi Techno Glass (Japan). Tissue culture chambers were purchased from Nalge Nunc International (USA).
Materials and Methods

Materials
Assay for Lipid Droplet Accumulation in Macrophages
The morphological assay for lipid droplet accumulation in mouse peritoneal macrophages was carried out according to the method described previously [33] . Briefly, primary mouse peritoneal macrophages (4ϫ10 5 cells in GIT medium) in each well of a tissue culture chamber were incubated in a humidified CO 2 (5% v/v) incubator at 37°C for 2 hours. The medium was then replaced with 0.2 ml of DMEM containing 7% (v/v) lipoprotein-deficient serum (LPDS), penicillin (100 units/ml) and streptomycin (100 mg/ml) (hereafter referred to as medium A). After a 2-hours preincubation, 2.0 m l of a sample in methanol, and 8.0 m l of liposomes (phosphatidylcholine 1.0 m mol, phosphatidylserine 1.0 m mol, dicetylphosphate 0.2 m mol and cholesterol 1.5 m mol, suspended in 1.0 ml of 0.3 M glucose) were added to each well. After a 14-hours incubation, the cells were washed with PBS and then fixed by soaking in 10% formalin. Nuclei and intracellular neutral lipid droplets were then stained with hematoxylin and oil red O, respectively. The lipid droplet accumulation and morphological changes in macrophages were examined by light microscopy (Vanox-S model, Olympus).
Assay for Neutral Lipid Synthesis in Macrophages
The assay for the synthesis of [
14 C] CE and [ 14 C]triacylglycerol (TG) synthesis from [
14 C]oleic acid in mouse peritoneal macrophages was carried out by our established method [33] . Briefly, mouse peritoneal macrophages (5ϫ10 5 cells in 250 ml of medium A) were cultured in each well of a 48-well plastic microplate, and then 2.5 m l of a test compound (methanol solution) and 10 ml of liposomes together with 5 ml of [1- 14 C]oleic acid (1 nmol, 1.85 KBq, 10% ethanol/PBS solution) were added to each culture at 37°C in 5% CO 2 . Following a 14-hours incubation, the medium was removed, and the cells in each well were washed twice with PBS. The cells were lysed by adding 0.25 ml of 10 mM Tris-HCl (pH 7.5) containing 0.1% (w/v) sodium dodecyl sulfate (SDS), and the cellular lipids were extracted by the method of Bligh and Dyer [34] . After the organic phase was concentrated, the total lipids were separated on a TLC plate (silica gel F254, 0.5 mm thick, Merck, Germany) and analyzed with a bioimaging analyzer (BAS 2000, Fuji Film, Japan).
Culture of ACAT1-and ACAT2-CHO Cells
ACAT1-CHO and ACAT2-CHO cells were cultured by the method described previously [9] . Briefly, both cell lines were maintained at 37°C in 5% CO 2 in Ham's F-12 medium supplemented with MEM vitamins, geneticin (300 mg/ml) and 10% heat inactivated FBS (hereafter referred to as medium B).
Assay for [
14 C]CE Synthesis in ACAT1-or ACAT2-CHO Cells ACAT1-or ACAT2-CHO cells (1.25ϫ10 5 cells in 250 ml of medium B) were cultured in a 48-well plastic microplate and allowed to recover overnight at 37°C in 5% CO 2 . The assays were done with cells that were at least 80% confluent. Following the overnight recovery, 2.5 m l of a sample (methanol solution) and 5 m l of [1- 14 C]oleic acid (1 nmol, 1.85 KBq, 10% ethanol/PBS solution) were added to each culture at 37°C in 5% CO 2 . After a 6-hours incubation, the medium was removed, and the cells in each well were washed twice with PBS. The cells were lysed by adding 0. 25 
Assay for ACAT Isozyme Activity in Microsomes ACAT1 and ACAT2 activities were determined by using microsomes prepared as described above as the enzyme source [35] . Briefly, an assay mixture containing 2.5 mg/ml BSA in buffer A and [1- [34] . After the organic solvent was removed by evaporation, lipids was separated on a TLC plate and the radioactivity of [ 14 C]CE was measured as described above.
Results
Inhibition of Lipid Droplet Accumulation and CE Synthesis in Macrophages
Microbial ACAT inhibitors previously discovered in an enzyme assay using rat liver microsomes (Fig. 1) were evaluated in assays for lipid droplet accumulation in macrophages. In this morphological assay, purpactins, glisoprenin A and terpendole C were found to inhibit lipid droplet accumulation in macrophages at 20 m M (data not shown). In the biochemical assay, they selectively inhibited CE synthesis in macrophages more than TG synthesis (Table 1) . Thus, purpactins, glisoprenin A and terpendole C inhibited CE synthesis because of blockage of ACAT activity in macrophages. On the other hand, pyripyropenes showed almost no effect on lipid droplet accumulation in macrophages even at 20 mM. Furthermore, pyripyropene A did not inhibit CE synthesis in macrophages, and the other pyripyropenes (B to D) showed extremely weak activity against CE synthesis, although they are the most potent ACAT inhibitors (with nM levels of IC 50 values) in rat liver microsomes. Beauvericin inhibited the synthesis of both CE and TG because of its cytotoxic effect on macrophages (IC 50 0.9 mM, data not shown). Synthetic urea CL-283,546 showed the most potent inhibition of CE synthesis (IC 50 0.035 m M) in macrophages among the ACAT inhibitors shown in Fig. 1 . Table 2 . Pyripyropenes were found to selectively inhibit ACAT2 activity. In particular, pyripyropene A was active only against ACAT2, with a selectivity index (SI) of Ͼ1,000, followed by pyripyropene C. Thus, pyripyropene A was confirmed to be the most selective ACAT2 inhibitor [9, 36] . Purpactins, glisoprenin A, terpendole C, beauvericin, spylidone, sespendole and CL-283,546 inhibited both ACAT1 and ACAT2 activities with SI values of 1.0 to 5.0. On the other hand, beauveriolides I and III selectively inhibited ACAT1 activity with SI values of 33 and Ͼ22, respectively. However, phenochalasin A, K97-0239A and B showed no or very weak activity against ACAT1 and ACAT2 as compared with their IC 50 values of CE synthesis (0.6, 1.5 and 1.7 mM, respectively [26, 27, 30] ) in the macrophage assay, indicating that their molecular targets in macrophages are not ACAT.
Selectivity of Microbial Inhibitors toward ACAT
2) Enzyme Assay Using Microsomes from ACAT1-and ACAT2-CHO Cells
The IC 50 values of microbial inhibitors in ACAT assays using microsomes prepared from ACAT1-and ACAT2-CHO cells are summarized in Table 2 . The IC 50 values in the enzyme assay generally showed good agreement with those in the cell-based assay using ACAT1-and ACAT2-CHO cells. However, beauveriolides I and III were found to inhibit both ACAT isozymes to similar extents in the enzyme assay although they showed selective inhibition against ACAT1 (SI, 33 and Ͼ22) in the cell-based assay.
Discussion
As summarized in Figs. 1 and 2 , our research group previously discovered a number of compounds which inhibited ACAT activity in rat liver microsomes (which mainly express ACAT2) and lipid droplet accumulation in intact macrophages (which express ACAT1) [37] . The compounds were (re-)evaluated in the several assay systems for CE synthesis as described in this study: lipid droplet accumulation in mouse macrophages, CE synthesis in ACAT1-and ACAT2-CHO cells and ACAT activity in microsomes prepared from ACAT1-and ACAT2-CHO cells.
The purposes of this study were as follows; 1) ACAT has been recognized as a potential target for the development of antiatherosclerotic agents, and a number of ACAT inhibitors have been reported. Recent studies of ACAT revealed that there are two isozymes, ACAT1 and ACAT2, with different functions in human body [3ϳ7]. However, the selectivity of microbial ACAT inhibitors toward ACAT1 and ACAT2 is only partially understood. Therefore, we aimed to assess their selectivity toward these isozymes. Microbial ACAT inhibitors (Fig. 1) were expected to inhibit at least ACAT2 because they were isolated based on the inhibition of ACAT activity in rat liver microsomes. Additionally, we tested whether these microbial ACAT inhibitors inhibited lipid droplet accumulation in mouse macrophages (via a process involving ACAT1).
2) The molecular targets of the microbial compounds (Fig. 2 ) discovered as inhibiting lipid droplet accumulation in macrophages were unknown. However, it was worthy testing whether they inhibit ACAT activity as one of the potential targets.
In this study, pyripyropene A was reconfirmed to be an ACAT2-selective inhibitor with the highest SI value (Ͼ1,000) among the agents studied [9, 36] . Accordingly, it is not surprising that it showed no effect on lipid droplet accumulation in macrophages (Table 1) . Interestingly, pyripyropenes B, C and D, having only a subtle difference in acyl chains from pyripyropene A (Fig. 1) 89) than that of pyripyropene A (Table 2) . Purpactins, glisoprenin A and terpendole C were found to inhibit both ACAT1 and ACAT2 to similar extents (SI, 1.0 to 2.3). Therefore, they inhibited lipid droplet accumulation in macrophages by selective blockage of CE synthesis catalyzed by ACAT1. However, beauvericin inhibited not only CE but also TG synthesis in macrophages although it inhibited ACAT1 and ACAT2, which can be explained by the fact that beauvericin has several molecular targets in eucaryotic cells such as ionophore activity, nonselective enzyme inhibition, etc.
[38ϳ40] and shows toxic effects on macrophages [31] .
Among the inhibitors of lipid droplet accumulation in macrophages (Fig. 2) , beauveriolides I and III, expected to provide leads for the development of a new type of antiatherosclerotic agent [31, 32] , were found to inhibit ACAT1 rather selectively (SI, 33 and Ͼ22, respectively) (Table 2) in the cell-based assays. Interestingly, ACAT assays using microsomes indicated that beauveriolides inhibited both isozymes almost equally (SI, 1.2 and 1.0), in accord with those in mouse liver and macrophage microsomes as previously reported [31] . Current research activities regarding ACAT is limited to cell biology and biochemistry due to the fact that the crystal structure of ACAT has not yet been determined as a result of difficulties associated with purification of this protein. ACAT1 and ACAT2 share extensive homology near their C termini, but not near their N termini [4] . Although the enzymological properties of ACAT isozymes are also very similar [41] , the exact membrane topology and the active site of ACAT isozymes remain unresolved. Joyce et al. reported that the active site of ACAT1 (Ser 269 ) is located in the cytoplasm, while that of ACAT2 (Ser 249 ) is located in the lumen [42] . On the other hand, Chang et al. reported that the active site of ACAT1 (His 460 ) and ACAT2 (His 434 ) is located in the transmembrane domain [43, 44] . The different effects of beauveriolides on the ACAT isozymes between the cellbased assay and enzyme assay might be due to the different distributions of the active sites of two ACAT isozymes in the ER, but this remains to be proven. Thus, pyripyropene A and beauveriolides are expected to not only provide leads for drug development but also useful probes to study the function of the ACAT isozymes.
The present findings made it clear that ACAT is not the molecular target of phenochalasin A and K97-0239s, because they showed no or very weak inhibition of ACAT1 and ACAT2. We also concluded that the molecular targets of spylidone could be ACAT1 and ACAT2. Sespendole also inhibited ACAT1 and ACAT2, but this compound also has a different target because it inhibited not only CE but TG synthesis in macrophages.
